202 related articles for article (PubMed ID: 37305389)
1. Apolipoprotein C1 promotes tumor progression in gastric cancer.
Gu Q; Zhan T; Guan X; Lai C; Lu NA; Wang G; Xu L; Gao X; Zhang J
Oncol Res; 2023; 31(3):287-297. PubMed ID: 37305389
[TBL] [Abstract][Full Text] [Related]
2. APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis.
Cao X; Wu B; Guo S; Zhong W; Zhu S; Zhang Z; Gu L; Li H
Pathol Oncol Res; 2023; 29():1610976. PubMed ID: 36969562
[No Abstract] [Full Text] [Related]
3. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer.
Yi J; Ren L; Wu J; Li W; Zheng X; Du G; Wang J
Ann Transl Med; 2019 Aug; 7(16):380. PubMed ID: 31555694
[TBL] [Abstract][Full Text] [Related]
5. Decreased APOC1 expression inhibited cancer progression and was associated with better prognosis and immune microenvironment in esophageal cancer.
Guo Q; Liu XL; Jiang N; Zhang WJ; Guo SW; Yang H; Ji YM; Zhou J; Guo JL; Zhang J; Liu HS
Am J Cancer Res; 2022; 12(11):4904-4929. PubMed ID: 36504892
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer.
Ren H; Chen Z; Yang L; Xiong W; Yang H; Xu K; Zhai E; Ding L; He Y; Song X
Cancer Manag Res; 2019; 11():4917-4930. PubMed ID: 31213910
[No Abstract] [Full Text] [Related]
7. High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer.
Deng H; Li T; Wei F; Han W; Xu X; Zhang Y
Pathol Oncol Res; 2023; 29():1610893. PubMed ID: 36741965
[No Abstract] [Full Text] [Related]
8. Systematic pan-cancer analysis identifies APOC1 as an immunological biomarker which regulates macrophage polarization and promotes tumor metastasis.
Ren L; Yi J; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang X; Wang J
Pharmacol Res; 2022 Sep; 183():106376. PubMed ID: 35914680
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Apolipoprotein C1 (APOC1) in Clear Cell Renal Cell Carcinoma and Its Prognostic Significance.
Xiao H; Xu Y
Med Sci Monit; 2021 Feb; 27():e929347. PubMed ID: 33591959
[TBL] [Abstract][Full Text] [Related]
10. ApoC1 promotes glioma metastasis by enhancing epithelial-mesenchymal transition and activating the STAT3 pathway.
Liang R; Zhang G; Xu W; Liu W; Tang Y
Neurol Res; 2023 Mar; 45(3):268-275. PubMed ID: 36302088
[TBL] [Abstract][Full Text] [Related]
11. The Apolipoprotein C1 is involved in breast cancer progression via EMT and MAPK/JNK pathway.
Zhang H; Wang Y; Liu C; Li W; Zhou F; Wang X; Zheng J
Pathol Res Pract; 2022 Jan; 229():153746. PubMed ID: 34952429
[TBL] [Abstract][Full Text] [Related]
12. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.
Mak TK; Li X; Huang H; Wu K; Huang Z; He Y; Zhang C
Front Immunol; 2022; 13():951214. PubMed ID: 35967313
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma.
Cui Y; Miao C; Hou C; Wang Z; Liu B
Front Oncol; 2020; 10():1436. PubMed ID: 32974161
[No Abstract] [Full Text] [Related]
15. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
16. ZNF460 mediates epithelial-mesenchymal transition to promote gastric cancer progression by transactivating APOC1 expression.
An L; Liu Y
Exp Cell Res; 2023 Jan; 422(2):113452. PubMed ID: 36563923
[TBL] [Abstract][Full Text] [Related]
17. Expression of apolipoprotein C1 in clear cell renal cell carcinoma: An oncogenic gene and a prognostic marker.
Wang HJ; Ma YX; Wang AH; Jiang YS; Jiang XZ
Kaohsiung J Med Sci; 2021 May; 37(5):419-426. PubMed ID: 33305507
[TBL] [Abstract][Full Text] [Related]
18. Correlation analysis of lipid metabolism genes with the immune microenvironment in gastric cancer and the construction of a novel gene signature.
Li Y; Chen X; Zhang R; Chen M; Shen J; Wu J; Yu J; Sun Q
Clin Transl Oncol; 2023 May; 25(5):1315-1331. PubMed ID: 36520384
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of the prognostic value and immune infiltration of
Yang C; Song D; Zhao F; Wu J; Zhang B; Ren H; Sun Q; Qin S
Front Oncol; 2022; 12():936952. PubMed ID: 36147913
[TBL] [Abstract][Full Text] [Related]
20. Immune activity score to assess the prognosis, immunotherapy and chemotherapy response in gastric cancer and experimental validation.
Wu X; Zhou F; Cheng B; Tong G; Chen M; He L; Li Z; Yu S; Wang S; Lin L
PeerJ; 2023; 11():e16317. PubMed ID: 38025711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
